- Home
- QSR vs BIIB Comparison
QSR vs BIIB Comparison
Compare QSR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSR
- BIIB
- Stock Information
- Founded
- QSR 1954
- BIIB 1978
- Country
- QSR Canada
- BIIB United States
- Employees
- QSR N/A
- BIIB N/A
- Industry
- QSR
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- QSR
- BIIB Health Care
- Exchange
- QSR Nasdaq
- BIIB Nasdaq
- Market Cap
- QSR N/A
- BIIB 18.8B
- IPO Year
- QSR 2006
- BIIB 1991
- Fundamental
- Price
- QSR $67.06
- BIIB $133.99
- Analyst Decision
- QSR Buy
- BIIB Buy
- Analyst Count
- QSR 19
- BIIB 27
- Target Price
- QSR $77.89
- BIIB $188.17
- AVG Volume (30 Days)
- QSR 4.0M
- BIIB 1.3M
- Earning Date
- QSR 08-07-2025
- BIIB 07-31-2025
- Dividend Yield
- QSR 3.68%
- BIIB N/A
- EPS Growth
- QSR N/A
- BIIB 26.39
- EPS
- QSR 2.94
- BIIB 10.12
- Revenue
- QSR $8,776,000,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- QSR $9.51
- BIIB N/A
- Revenue Next Year
- QSR $3.22
- BIIB N/A
- P/E Ratio
- QSR $22.92
- BIIB $13.29
- Revenue Growth
- QSR 22.38
- BIIB 1.59
- 52 Week Low
- QSR $58.71
- BIIB $110.04
- 52 Week High
- QSR $75.07
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- QSR 50.67
- BIIB 56.84
- Support Level
- QSR $67.04
- BIIB $129.08
- Resistance Level
- QSR $68.78
- BIIB $137.84
- Average True Range (ATR)
- QSR 1.16
- BIIB 4.01
- MACD
- QSR 0.19
- BIIB 0.57
- Stochastic Oscillator
- QSR 73.35
- BIIB 70.81
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.